Guide

Microdose Semaglutide 2026: Cost, and What the Evidence Does Not Say

Microdose programmes use doses below the approved starting dose. The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than ful

Dr. Parmis, Editorial Lead · Jonathan Michael Snipes, MD, Medical Reviewer

Published 2026-08-03Updated 2026-08-03Sources captured 2026-08-03Medically reviewed not yet — why

Direct answer

Microdose programmes use doses below the approved starting dose. The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than full dose. The evidence position matters more than the price: microdoses sit below every dose studied in STEP-1, so no published efficacy figure applies to them at any price.

Answer last reviewed: 2026-08-03

What is microdosing, in plain terms?

Approved labelling for chronic weight management describes a schedule beginning at 0.25 mg weekly and stepping up to a 2.4 mg maintenance dose. A microdose programme uses amounts below that starting dose.

People choose it for tolerability, because gastrointestinal effects cluster at each dose increase, and for maintenance after reaching a goal. Both are plausible. Neither has been tested in a trial of this molecule at these doses.

The evidence position

STEP-1 studied 2.4 mg. SELECT studied 2.4 mg. A microdose is below the lowest dose in either.

So the 14.9% weight-loss figure and the 20% cardiovascular risk reduction do not describe what a microdose programme delivers. Anyone quoting those numbers beside a microdose price is quoting evidence that was not collected on the product being sold.

We say this on the page that also carries the prices, because a reader deciding on cost deserves the evidence position in the same place.

What does it cost against a full dose?

Microdose against full dose, same provider, same terms
Term	Microdose	Full dose	Difference
Month-to-month	$129	$165	−$36
3-month	$117	$149	−$32
6-month	$114	$147	−$33
12-month	$110	$145	−$35
Twelve-month total	$1,320	$1,740	−$420

About $420 a year separates them. That is a real saving, and it buys a product whose dose sits outside the trial evidence.

Why is the cheapest row not automatically the best buy?

Ranked on price alone a microdose programme wins every table it appears in. That is precisely why we keep the protocols separate: a microdose figure and a full-dose figure are not comparable, and a comparison site that sorts them together produces a ranking that is arithmetically correct and practically misleading.

What should I ask before starting?

What dose, in milligrams? “Microdose” is a marketing word, not a defined quantity.
What is the clinical rationale for me specifically? Since 2025 the surviving compounding route requires a prescriber to document a clinical difference for the individual patient.
Does the price change if I move to a full dose? On the programme we captured it does.
What evidence are you relying on? If the answer quotes STEP-1, it is quoting a dose the programme does not supply.

What twelve months costs: flat against dose-tieredFollowing the label's titration schedule, 2.5 mg to a maintenance dose

Show this figure as a table

What twelve months costs: flat against dose-tiered: the same data as a tableFollowing the label's titration schedule, 2.5 mg to a maintenance dose

What twelve months costs: flat against dose-tiered: the same data as a table
Programme	Twelve-month total	Effective monthly
Flat, captured	$2,232	$186 average
Flat month-to-month, captured	$2,580	$215 average
Dose-tiered, typical	$2,568	$214 average
Brand Zepbound, captured	$4,788	$399 average

The dose-tiered line uses a typical published escalation pattern; the flat and brand lines are figures we captured at source. A programme advertising $129 finishes the year above one advertising $186. That crossover is the argument this whole site is built on. How we record price structure.

What is the salt-form question?

Semaglutide sodium and semaglutide acetate are not the same active ingredient as the base form in Wegovy and Ozempic, and the FDA has said they are not appropriate for compounding. Ask for the exact salt form and concentration in writing. Tirzepatide has no equivalent question.

How does every provider score on the six tests?

Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.

Every provider against the six testsComputed from the dataset on 2026-08-03 · 30 providers evaluated

Every provider against the six tests
Provider	Captured at source	Publishes a maintenance-dose price	One published structure	Names its fulfilling pharmacy	Answered all four disclosure questions	No figure we had to withdraw	Score
Mochi Health	Yes	Yes	Yes	Yes	—	Yes	5 of 6
NexLife	Yes	Yes	Yes	Yes	—	Yes	5 of 6
Fifty 410	Yes	—	Yes	—	—	Yes	3 of 6
LillyDirect	Yes	—	Yes	—	—	Yes	3 of 6
Trimi	Yes	—	Yes	—	—	Yes	3 of 6
Calibrate	—	—	Yes	—	—	Yes	2 of 6
Enhance.MD	—	—	Yes	—	—	Yes	2 of 6
Form Health	—	—	Yes	—	—	Yes	2 of 6

Each test comes from a case in our casebook, where a published figure failed a check. The table is generated from the records, not written.

The result, as of 2026-08-03

No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.

That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.

Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.

Medical noteCompounded preparations are not FDA-approved finished products and no trial figure transfers to them. Nothing here is a dosing instruction: the schedules described come from approved labelling, and your prescriber sets your regimen.

Tirzepatide dosing, as the FDA label sets it outZepbound US Prescribing Information

Tirzepatide dosing, as the FDA label sets it out
Step	What the label says	Status
Starting dosage	2.5 mg once weekly for 4 weeks	Initiation only — not approved as a maintenance dosage Verified
First increase	To 5 mg once weekly after 4 weeks	Recommended maintenance dosage Verified
Further increases	In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response	A minimum interval, not a fixed calendar Verified
7.5 mg and 12.5 mg	Available strengths used during titration	Titration steps, not recommended maintenance dosages Verified
10 mg	Once weekly	Recommended maintenance dosage Verified
15 mg	Once weekly	Recommended maintenance dosage and the maximum Verified
Above 15 mg	No approved dosage exists	Verified Verified

Escalation is driven by tolerability and response, not by a calendar. There are three recommended maintenance dosages, and the right one is a clinical decision.

Why 'cheapest' needs a definition attached

Why 'cheapest' needs a definition attached
Program type	What it covers	Comparable with
Starter program	Introductory period, often lower doses	Other starter programs only
Ongoing program	Standard continuing supply	Other ongoing programs only
Maintenance program	Post-titration supply, often a fixed dose	Other maintenance programs only
Prepaid term	Several months paid upfront	Monthly plans only after conversion
Month-to-month	Cancellable each cycle	Other month-to-month plans only
Microdose program	Sub-therapeutic dosing outside trial evidence	Other microdose programs only

Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.

Frequently asked questions

Does microdosing semaglutide work?

No published trial has tested semaglutide at microdoses for weight management. STEP-1 and SELECT both studied 2.4 mg, above the range microdose programmes use.

How much does microdose semaglutide cost?

The cheapest we captured is $110 a month on a twelve-month plan, $1,320 a year — about $420 less than the same provider's full-dose programme.

What counts as a microdose?

There is no defined quantity. It is a marketing term for amounts below the approved 0.25 mg starting dose. Ask any provider for the figure in milligrams.

The 100-point rubricCore & Trust
Cost calculatorTools
The underlying price recordsData
Microdose vs Standard-Dose TirzepatideComparisons
Microdose Tirzepatide: Evidence, Cost and LimitationsPillar / Money
Microdose Tirzepatide: The Evidence GapJournal
Provider and Study Source LedgerData
Open GLP-1 Data and Evidence LibraryData
GLP-1 Tirzepatide Rank: Evidence, Prices, Providers & ToolsCore & Trust
How Dose Escalation Changes Tirzepatide CostJournal

Cite this pageCC BY 4.0

GLP-1 Tirzepatide Rank. “Microdose Semaglutide 2026: Cost, and What the Evidence Does Not Say.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/microdose-semaglutide-2026/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.